Avantor (AVTR)

• Market cap: $8.76B
• 1 day: -3.38%
• 5 days: 7.53%
• 1 month: -17.42%
• 3 months: -28.09%
• 6 months: -39.24%
• Year to date: -39.39%
• 1 year: -48.83%
• 5 years: -27.61%
• 10 years: -11.38%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.

Employees: 13,500

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1.03% more ownership

Funds ownership: 99.39% [Q3] → 100.42% (+1.03%) [Q4]

5% less funds holding

Funds holding: 503 [Q3] → 478 (-25) [Q4]

17% less capital invested

Capital invested by funds: $17.5B [Q3] → $14.4B (-$3.05B) [Q4]

19% less repeat investments, than reductions

Existing positions increased: 166 | Existing positions reduced: 205

22% less first-time investments, than exits

New positions opened: 62 | Existing positions closed: 79

23% less funds holding in top 10

Funds holding in top 10: 13 [Q3] → 10 (-3) [Q4]

64% less call options, than puts

Call options by funds: $52.6M | Put options by funds: $145M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 9% upside
• Avg. target: $16.88 31% upside
• High target: $22 71% upside

8 analyst ratings

• positive: 4 50%
• neutral: 4 50%
• negative: 0 0%

Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target	9% upside $14	Neutral Downgraded	29 Apr 2025
RBC Capital Conor McNamara 10% 1-year accuracy 4 / 41 met price target	56% upside $20	Outperform Maintained	28 Apr 2025
Stifel Daniel Arias 11% 1-year accuracy 2 / 19 met price target	9% upside $14	Hold Downgraded	28 Apr 2025
Barclays Luke Sergott 33% 1-year accuracy 21 / 63 met price target	17% upside $15	Overweight Maintained	28 Apr 2025
Morgan Stanley Tejas Savant 30% 1-year accuracy 6 / 20 met price target	17% upside $15	Equal-Weight Downgraded	28 Apr 2025